Effectiveness of amlodipine-valsartan single-pill combinations: Hierarchical modeling of blood pressure and total cardiovascular disease risk outcomes (the excellent study)

Robert Lins, Ann Aerts, Nicolas Coen, Christine Hermans, Karen Macdonald, Heidi Brié, Christopher Lee, Yu Ming Shen, Stefaan Vancayzeele, Natalie Mecum, Ivo Abraham

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

BACKGROUND: Both patient- and physician-related factors have been shown to explain variability in the outcomes of antihypertensive treatment. Total cardiovascular risk (TCVR) is increasingly used as a determinant of treatment effectiveness but has also been proposed as a treatment outcome. To our knowledge, no studies have reported how antihypertensive treatment impacts blood pressure and TCVR outcomes. OBJECTIVE: To examine in patients treated with a regimen including single-pill combinations (SPCs) of amlodipine/valsartan (1) blood pressure (BP) reduction and control, total cardiovascular risk (TCVR) change, and TCVR reduction of 1 class or more; (2) hierarchical patient- and physician-level determinants of these outcomes; and (3) predictors of uncontrolled BP and improved TCVR classification. METHODS: A prospective (90 days), multicenter, multilevel pharmacoepidemiologic study was conducted in 3546 patients with hypertension treated with SPC amlodipine/valsartan by 698 general practitioners. Statistical analysis included hierarchical linear and logistic modeling of BP and TCVR outcomes. RESULTS: Mean (SD) systolic BP (SBP) reductions were 20.1 (15.5) mm Hg and diastolic BP (DBP) reductions were 9.8 (10.3) mm Hg, with higher reductions among high-risk patients. SBP, DBP, and SBP/DBP control rates were 33.3%, 45.3%, and 25.5%, respectively, with lower rates among high-risk patients. Mean TCVR improvement was a reduction of 0.73 (0.96) classes (-4 [best] to +4 [worst]), with higher reductions for high-risk patients; 58.2% of patients achieved a TCVR reduction of 1 or more classes, with lower percentages for high-risk patients. Twenty-two percent of systolic variability and 26% of diastolic variability in 90-day BP values were attributable to a physician class effect, as was 16% of TCVR change. CONCLUSIONS: Regimens that include SPC amlodipine/valsartan formulations are effective in reducing BP and TCVR in a real-world observational setting. Hierarchical modeling identified patient- and physician-related determinants of BP values and TCVR change, as well as independent predictors of uncontrolled BP and reduced TCVR. TCVR is a scientifically feasible and clinically relevant effectiveness outcome of antihypertensive treatment.

Original languageEnglish (US)
Pages (from-to)727-739
Number of pages13
JournalAnnals of Pharmacotherapy
Volume45
Issue number6
DOIs
StatePublished - Jun 2011
Externally publishedYes

Fingerprint

Cardiovascular Diseases
Outcome Assessment (Health Care)
Blood Pressure
Risk Reduction Behavior
Antihypertensive Agents
Physicians
Valsartan Drug Combination Amlodipine
General Practitioners
Hypertension

Keywords

  • Amlodipine
  • Cardiovascular risk
  • Effectiveness
  • Hypertension
  • Pharmacoepidemiology
  • Single-pill combination
  • Valsartan

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Effectiveness of amlodipine-valsartan single-pill combinations : Hierarchical modeling of blood pressure and total cardiovascular disease risk outcomes (the excellent study). / Lins, Robert; Aerts, Ann; Coen, Nicolas; Hermans, Christine; Macdonald, Karen; Brié, Heidi; Lee, Christopher; Shen, Yu Ming; Vancayzeele, Stefaan; Mecum, Natalie; Abraham, Ivo.

In: Annals of Pharmacotherapy, Vol. 45, No. 6, 06.2011, p. 727-739.

Research output: Contribution to journalArticle

Lins, R, Aerts, A, Coen, N, Hermans, C, Macdonald, K, Brié, H, Lee, C, Shen, YM, Vancayzeele, S, Mecum, N & Abraham, I 2011, 'Effectiveness of amlodipine-valsartan single-pill combinations: Hierarchical modeling of blood pressure and total cardiovascular disease risk outcomes (the excellent study)', Annals of Pharmacotherapy, vol. 45, no. 6, pp. 727-739. https://doi.org/10.1345/aph.1P663
Lins, Robert ; Aerts, Ann ; Coen, Nicolas ; Hermans, Christine ; Macdonald, Karen ; Brié, Heidi ; Lee, Christopher ; Shen, Yu Ming ; Vancayzeele, Stefaan ; Mecum, Natalie ; Abraham, Ivo. / Effectiveness of amlodipine-valsartan single-pill combinations : Hierarchical modeling of blood pressure and total cardiovascular disease risk outcomes (the excellent study). In: Annals of Pharmacotherapy. 2011 ; Vol. 45, No. 6. pp. 727-739.
@article{bca98a92164d48dba7993667c3fa9bd1,
title = "Effectiveness of amlodipine-valsartan single-pill combinations: Hierarchical modeling of blood pressure and total cardiovascular disease risk outcomes (the excellent study)",
abstract = "BACKGROUND: Both patient- and physician-related factors have been shown to explain variability in the outcomes of antihypertensive treatment. Total cardiovascular risk (TCVR) is increasingly used as a determinant of treatment effectiveness but has also been proposed as a treatment outcome. To our knowledge, no studies have reported how antihypertensive treatment impacts blood pressure and TCVR outcomes. OBJECTIVE: To examine in patients treated with a regimen including single-pill combinations (SPCs) of amlodipine/valsartan (1) blood pressure (BP) reduction and control, total cardiovascular risk (TCVR) change, and TCVR reduction of 1 class or more; (2) hierarchical patient- and physician-level determinants of these outcomes; and (3) predictors of uncontrolled BP and improved TCVR classification. METHODS: A prospective (90 days), multicenter, multilevel pharmacoepidemiologic study was conducted in 3546 patients with hypertension treated with SPC amlodipine/valsartan by 698 general practitioners. Statistical analysis included hierarchical linear and logistic modeling of BP and TCVR outcomes. RESULTS: Mean (SD) systolic BP (SBP) reductions were 20.1 (15.5) mm Hg and diastolic BP (DBP) reductions were 9.8 (10.3) mm Hg, with higher reductions among high-risk patients. SBP, DBP, and SBP/DBP control rates were 33.3{\%}, 45.3{\%}, and 25.5{\%}, respectively, with lower rates among high-risk patients. Mean TCVR improvement was a reduction of 0.73 (0.96) classes (-4 [best] to +4 [worst]), with higher reductions for high-risk patients; 58.2{\%} of patients achieved a TCVR reduction of 1 or more classes, with lower percentages for high-risk patients. Twenty-two percent of systolic variability and 26{\%} of diastolic variability in 90-day BP values were attributable to a physician class effect, as was 16{\%} of TCVR change. CONCLUSIONS: Regimens that include SPC amlodipine/valsartan formulations are effective in reducing BP and TCVR in a real-world observational setting. Hierarchical modeling identified patient- and physician-related determinants of BP values and TCVR change, as well as independent predictors of uncontrolled BP and reduced TCVR. TCVR is a scientifically feasible and clinically relevant effectiveness outcome of antihypertensive treatment.",
keywords = "Amlodipine, Cardiovascular risk, Effectiveness, Hypertension, Pharmacoepidemiology, Single-pill combination, Valsartan",
author = "Robert Lins and Ann Aerts and Nicolas Coen and Christine Hermans and Karen Macdonald and Heidi Bri{\'e} and Christopher Lee and Shen, {Yu Ming} and Stefaan Vancayzeele and Natalie Mecum and Ivo Abraham",
year = "2011",
month = "6",
doi = "10.1345/aph.1P663",
language = "English (US)",
volume = "45",
pages = "727--739",
journal = "Annals of Pharmacotherapy",
issn = "1060-0280",
publisher = "Harvey Whitney Books Company",
number = "6",

}

TY - JOUR

T1 - Effectiveness of amlodipine-valsartan single-pill combinations

T2 - Hierarchical modeling of blood pressure and total cardiovascular disease risk outcomes (the excellent study)

AU - Lins, Robert

AU - Aerts, Ann

AU - Coen, Nicolas

AU - Hermans, Christine

AU - Macdonald, Karen

AU - Brié, Heidi

AU - Lee, Christopher

AU - Shen, Yu Ming

AU - Vancayzeele, Stefaan

AU - Mecum, Natalie

AU - Abraham, Ivo

PY - 2011/6

Y1 - 2011/6

N2 - BACKGROUND: Both patient- and physician-related factors have been shown to explain variability in the outcomes of antihypertensive treatment. Total cardiovascular risk (TCVR) is increasingly used as a determinant of treatment effectiveness but has also been proposed as a treatment outcome. To our knowledge, no studies have reported how antihypertensive treatment impacts blood pressure and TCVR outcomes. OBJECTIVE: To examine in patients treated with a regimen including single-pill combinations (SPCs) of amlodipine/valsartan (1) blood pressure (BP) reduction and control, total cardiovascular risk (TCVR) change, and TCVR reduction of 1 class or more; (2) hierarchical patient- and physician-level determinants of these outcomes; and (3) predictors of uncontrolled BP and improved TCVR classification. METHODS: A prospective (90 days), multicenter, multilevel pharmacoepidemiologic study was conducted in 3546 patients with hypertension treated with SPC amlodipine/valsartan by 698 general practitioners. Statistical analysis included hierarchical linear and logistic modeling of BP and TCVR outcomes. RESULTS: Mean (SD) systolic BP (SBP) reductions were 20.1 (15.5) mm Hg and diastolic BP (DBP) reductions were 9.8 (10.3) mm Hg, with higher reductions among high-risk patients. SBP, DBP, and SBP/DBP control rates were 33.3%, 45.3%, and 25.5%, respectively, with lower rates among high-risk patients. Mean TCVR improvement was a reduction of 0.73 (0.96) classes (-4 [best] to +4 [worst]), with higher reductions for high-risk patients; 58.2% of patients achieved a TCVR reduction of 1 or more classes, with lower percentages for high-risk patients. Twenty-two percent of systolic variability and 26% of diastolic variability in 90-day BP values were attributable to a physician class effect, as was 16% of TCVR change. CONCLUSIONS: Regimens that include SPC amlodipine/valsartan formulations are effective in reducing BP and TCVR in a real-world observational setting. Hierarchical modeling identified patient- and physician-related determinants of BP values and TCVR change, as well as independent predictors of uncontrolled BP and reduced TCVR. TCVR is a scientifically feasible and clinically relevant effectiveness outcome of antihypertensive treatment.

AB - BACKGROUND: Both patient- and physician-related factors have been shown to explain variability in the outcomes of antihypertensive treatment. Total cardiovascular risk (TCVR) is increasingly used as a determinant of treatment effectiveness but has also been proposed as a treatment outcome. To our knowledge, no studies have reported how antihypertensive treatment impacts blood pressure and TCVR outcomes. OBJECTIVE: To examine in patients treated with a regimen including single-pill combinations (SPCs) of amlodipine/valsartan (1) blood pressure (BP) reduction and control, total cardiovascular risk (TCVR) change, and TCVR reduction of 1 class or more; (2) hierarchical patient- and physician-level determinants of these outcomes; and (3) predictors of uncontrolled BP and improved TCVR classification. METHODS: A prospective (90 days), multicenter, multilevel pharmacoepidemiologic study was conducted in 3546 patients with hypertension treated with SPC amlodipine/valsartan by 698 general practitioners. Statistical analysis included hierarchical linear and logistic modeling of BP and TCVR outcomes. RESULTS: Mean (SD) systolic BP (SBP) reductions were 20.1 (15.5) mm Hg and diastolic BP (DBP) reductions were 9.8 (10.3) mm Hg, with higher reductions among high-risk patients. SBP, DBP, and SBP/DBP control rates were 33.3%, 45.3%, and 25.5%, respectively, with lower rates among high-risk patients. Mean TCVR improvement was a reduction of 0.73 (0.96) classes (-4 [best] to +4 [worst]), with higher reductions for high-risk patients; 58.2% of patients achieved a TCVR reduction of 1 or more classes, with lower percentages for high-risk patients. Twenty-two percent of systolic variability and 26% of diastolic variability in 90-day BP values were attributable to a physician class effect, as was 16% of TCVR change. CONCLUSIONS: Regimens that include SPC amlodipine/valsartan formulations are effective in reducing BP and TCVR in a real-world observational setting. Hierarchical modeling identified patient- and physician-related determinants of BP values and TCVR change, as well as independent predictors of uncontrolled BP and reduced TCVR. TCVR is a scientifically feasible and clinically relevant effectiveness outcome of antihypertensive treatment.

KW - Amlodipine

KW - Cardiovascular risk

KW - Effectiveness

KW - Hypertension

KW - Pharmacoepidemiology

KW - Single-pill combination

KW - Valsartan

UR - http://www.scopus.com/inward/record.url?scp=79958824440&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958824440&partnerID=8YFLogxK

U2 - 10.1345/aph.1P663

DO - 10.1345/aph.1P663

M3 - Article

C2 - 21666094

AN - SCOPUS:79958824440

VL - 45

SP - 727

EP - 739

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

SN - 1060-0280

IS - 6

ER -